Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases
Volume 12, Issue 1, Pages 13-14
http://dx.doi.org/10.1155/2001/319279
Paediatric Infectious Disease Note

Nevirapine Use to Reduce Mother-To-Child Transmission of HIV in Canada

Committee for Canadian Paediatric AIDS Research Group

Copyright © 2001 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that is used to treat adults and children with human immunodeficiency virus (HIV) infection. The drug was licensed in Canada in September 1998 and has been widely used in combination antiretroviral therapy regimens, usually along with two nucleoside reverse transcriptase inhibitors. NVP is, generally, well tolerated; however, up to 20% of patients may develop rash, with a severe rash occurring in 6% of patients and Stevens-Johnson syndrome reported in 0.5% of patients. A large number of NNRTI mutations have been documented, and a single mutation, K103N, confers a degree of broad NNRTI resistance. Distinctions occur in resistance patterns to different NNRTIs (1).